|
Thomas F. Miller is responsible for directing the commercial strategy for the Company's SRT pipeline including Surfaxin® and Aerosurf life cycle as well as other novel SRT formulations. Dr. Miller initially joined Discovery Labs in August 2004 as Vice President, Worldwide Marketing. He brings with him over 14 years of relevant experience which includes multiple leadership assignments at global pharmaceutical companies. Prior to joining Discovery, Dr. Miller served as the Director of Global Biologics Strategic Marketing at Centocor, a Johnson & Johnson biotechnology company, where he was responsible for the development of global business strategy for emerging, niche-market products. Previously, he held commercial and scientifically-related positions of increasing responsibility at Pharmacia, BASF Pharma, and Pfizer. Dr. Miller holds a B.S. Degree in Biology from Fairfield University, a MBA degree from Fairleigh Dickinson University and a Ph.D. in Cardio-respiratory physiology from Temple University School of Medicine, where his research focus was respiratory insufficiency and critical care intervention in neonates. | 